Lantus is the brand name for insulin glargine, a long-acting basal insulin analog manufactured by Sanofi. Insulin glargine works by providing a steady, 24-hour background level of insulin that helps control blood glucose between meals and overnight. Lantus is FDA-approved for adults and pediatric patients (age 6 and older) with type 1 diabetes, and for adults with type 2 diabetes who require basal insulin. Toujeo is Sanofi's higher-concentration (300 units/mL) version of the same molecule, available in a prefilled pen.
Sanofi cut Lantus's U.S. list price by 78 percent in March 2023, bringing the catalog price from approximately $292 per vial to about $63 per vial for commercially insured patients. However, prices vary widely across pharmacy channels and insurance configurations. In 2026, retail cash prices at major pharmacies typically run $285 per 10 mL vial or $422 per box of five SoloSTAR pens before any discount programs are applied. The Sanofi Valyou Savings Program is the fastest path to $35 per month for patients paying cash. For patients with Medicare Part D coverage, the Inflation Reduction Act mandates a $35-per-month insulin cap with no deductible phase. Patients considering a switch should compare the formulary tier and prior authorization requirements for Semglee, Basaglar, and Rezvoglar with their specific plan, as biosimilar alternatives often land on preferred formulary tiers at lower cost-share.
Lantus is not among the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act of 2022. CMS excluded insulin glargine from Round 1 negotiations because biosimilar competition already exists, making the statutory single-source negotiation threshold inapplicable. Unlike the 10 Round-1 drugs (such as Eliquis and Jardiance) that carry a Maximum Fair Price effective January 1, 2026, Lantus has no CMS-negotiated Maximum Fair Price. Insulin glargine does benefit from the IRA's separate insulin-specific provision: the $35-per-month Part D cap for all Medicare beneficiaries, effective 2023. Patients who want to understand overall Medicare Part D out-of-pocket costs should note that the 2026 annual out-of-pocket cap across all Part D drugs is $2,100, though the dedicated insulin cap of $35 per month is more favorable for most insulin users and applies independently. Commercially insured patients who are not on Medicare can also ask their pharmacist about a manufacturer coupon or savings card from Sanofi; the Valyou program functions like a manufacturer coupon that caps Lantus at $35 for cash-paying patients. For a broader look at insulin costs, see the insulin cost guide.
What Lantus Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same lantus can cost many times more at a hospital than at your local pharmacy:
2026 Lantus Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $285 - $422/month | Retail price without insurance or discount program for a vial or SoloSTAR pen box. Use Sanofi Valyou or GoodRx coupon to access $35/month instead. |
| Medicare Part D (2026) | $35/month maximum (IRA insulin cap) | No deductible phase for insulin; $35 cap applies at all benefit phases. Effective January 1, 2023 under the Inflation Reduction Act. |
| Commercial insurance | $0 - $50/month copay | Formulary tier placement varies by plan. Prior authorization is common for brand Lantus when a biosimilar is on the preferred tier. |
| Sanofi Valyou Savings Program | $35/month (uninsured or cash-pay only) | Not available to Medicare, Medicaid, TRICARE, or VA beneficiaries. Requires filling all Sanofi insulin prescriptions simultaneously each month. |
| Medicaid | $1 - $4/prescription | Covered in all 50 states; copay varies by state. Medicaid income limits vary by state; check your state Medicaid agency for eligibility. |
Retail prices reflect 2026 GoodRx and pharmacy survey data. Medicare Part D rates reflect IRA 2022 insulin cap. Sanofi Valyou program terms verified June 2026 via lantus.com.
Source: Sanofi Valyou Savings Program, CMS Medicare Part D 2026, GoodRx pharmacy pricing
Why Hospitals Charge So Much
Lantus and other basal insulins are among the most commonly used medications in inpatient settings. When a patient with diabetes is admitted, hospitals typically administer insulin continuously during the stay. Under Medicare's Diagnosis-Related Group (DRG) payment system, most insulin administered during an inpatient stay is bundled into the flat DRG payment. Patients covered by Medicare and most commercial insurance plans should not see a separate line-item charge for Lantus on an inpatient facility bill, because the insulin cost is absorbed into the bundled rate the hospital receives.
Billing problems arise when hospitals charge for insulin separately despite the DRG bundling rule, or when a patient with no insurance is admitted and the hospital applies its full chargemaster rate instead of a DRG-equivalent rate. In those cases, Lantus can appear on an itemized bill at $500 to $1,200 or more for a single admission. Three factors drive this markup: the hospital's full chargemaster acquisition cost (which may predate Sanofi's 2023 price cut), pharmacy handling and preparation fees, and nursing administration charges. If you see Lantus listed as a separate line item at more than $100 for a short inpatient stay, request an itemized bill and ask the billing department whether the DRG or per-diem bundling was applied correctly. Charges significantly above the retail cost of one vial ($285) for a brief stay are a strong dispute target.
Patients who receive insulin at an outpatient infusion center or clinic where the drug is administered by a healthcare professional may be billed under Medicare Part B rather than Part D, using the billing code J1817 (insulin glargine, per unit). In that narrow context, a Medicare Part B patient would pay 20 percent coinsurance after the 2026 Part B deductible of $283. For the vast majority of Lantus users who self-inject at home, the Part D pathway applies and the $35-per-month Medicare insulin cap is the relevant cost-sharing rule. If you receive a Part B explanation of benefits showing a Lantus charge far above the Medicare-allowed amount, use the medical bill analyzer to identify whether the claim was billed correctly.
Patient Assistance Programs
Sanofi operates two distinct programs that can lower Lantus costs significantly: the Valyou Savings Program (a point-of-sale savings card for uninsured and cash-paying patients) and the Sanofi Patient Connection patient assistance program (free drug for income-eligible patients who have no prescription drug insurance). Understanding which program applies to your situation determines how you apply and what you pay.
Patient assistance programs for Lantus| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Sanofi Valyou Savings Program | $35 per 30-day supply for uninsured or cash-paying patients (not for Medicare/Medicaid) | lantus.com/sign-up-for-savings |
| Sanofi Patient Connection (Patient Assistance Program) | Free Lantus for uninsured patients with household income at or below 400% of the Federal Poverty Level | sanofipatientconnection.com |
| NeedyMeds Drug Discount Program | Variable discount on insulin glargine and biosimilars at most US pharmacies; free card | needymeds.org |
Manufacturer savings cards and copay programs are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries under federal anti-kickback statute (42 U.S.C. § 1320a-7b). This prohibition includes the Sanofi Valyou Savings Program. Medicare beneficiaries pay the statutory $35-per-month insulin cap through their Part D plan. If you have Medicare and cannot afford your insulin copay, apply for Medicare Extra Help (Low Income Subsidy) at ssa.gov/extrahelp, which can reduce Part D cost-sharing further. If you have no insurance, apply for the income-based Sanofi Patient Connection program instead of the Valyou card.
Source: Sanofi Patient Connection (sanofipatientconnection.com), Sanofi Valyou Savings Program (lantus.com), NeedyMeds.org
Medicare Part D Coverage for Lantus
Lantus is a Medicare Part D drug. Under the Inflation Reduction Act of 2022, Medicare Part D plans must cap insulin copays at $35 per month for all covered insulins, including insulin glargine. This cap applies at all benefit phases (deductible, initial coverage, and coverage gap) and took effect January 1, 2023. In 2026, you pay no more than $35 for each covered insulin per 30-day supply, regardless of which benefit phase your plan is in. The annual Part D out-of-pocket cap of $2,100 also applies to Lantus, but the $35 monthly insulin cap is almost always more favorable and controls your Lantus cost-sharing throughout the year.
Medicare covers Lantus under most Part D plans when prescribed for type 1 or type 2 diabetes. Your plan may require prior authorization, particularly if it has placed a biosimilar like Semglee or Basaglar on a preferred tier. If your plan requires step therapy (using a biosimilar before brand Lantus), your prescriber can file a step-therapy override or medical exception if you have a documented clinical reason to stay on Lantus. The Medicare Prescription Payment Plan, available starting in 2025, lets you spread your annual Part D cost-sharing evenly across 12 monthly payments if a large early-year insulin bill creates a cash-flow problem. Ask your Part D plan about enrolling.
Lantus was not selected for IRA Round 1 Medicare price negotiation. CMS excluded insulin glargine from the negotiation list because multiple FDA-approved biosimilars already compete in the market, a condition that disqualifies a drug from the small-molecule negotiation track. This exclusion does not affect the $35-per-month insulin cap, which remains in full force for all Medicare beneficiaries regardless of whether a drug was negotiated. Patients looking for ways to reduce costs further should ask their prescriber whether Semglee (the interchangeable biosimilar to Lantus) is medically appropriate, as interchangeable biosimilars can be automatically substituted at the pharmacy in most states without a new prescription.
Common Lantus Billing Errors
If your bill for Lantus or insulin glargine looks higher than expected, check for these common billing issues before paying:
- Charged Medicare Part B rate for a self-administered injection: Lantus billed as J1817 (Part B code) when you self-inject at home is incorrect. Self-administered insulin belongs in Part D, not Part B.
- Formulary tier placed incorrectly: your plan may have moved Lantus to a higher non-preferred tier while a biosimilar sits on the preferred tier. Appeal the tier-exception or switch to the biosimilar alternative.
- Charged a deductible phase copay on insulin: under the IRA, insulin has no Part D deductible phase. If you are charged a deductible-phase amount for Lantus, call your plan immediately.
- Inpatient Lantus billed separately from the DRG: most hospital insulin charges should be bundled. A separate line item for Lantus during an inpatient stay covered by Medicare or commercial insurance is often a billing error.
- Valyou Savings Program not applied despite enrollment: if you enrolled in the Sanofi Valyou program but the pharmacy charged full retail, ask the pharmacist to re-process the claim using the savings program BIN/PCN number.
Frequently Asked Questions
Is there a generic or biosimilar for Lantus in 2026?
Lantus is a biologic, so it does not have a traditional small-molecule generic. However, three FDA-approved biosimilars are available as of 2026: Semglee (Viatris/Biocon), Rezvoglar (Eli Lilly), and Basaglar (Eli Lilly). Semglee and Rezvoglar are designated interchangeable biosimilars, meaning a pharmacist can substitute them for Lantus without a new prescription from your doctor in most states. A fourth interchangeable biosimilar, Langlara, received FDA approval in May 2026. Biosimilars typically cost 15 to 65 percent less than brand Lantus and are often placed on preferred formulary tiers by insurance plans.
How do I apply for the Sanofi Patient Connection patient assistance program?
Visit sanofipatientconnection.com or call 1-888-847-4877 (Monday to Friday, 9 AM to 8 PM ET). Select your state to download the correct application. You will need: proof of household income (last tax return or four consecutive pay stubs), a valid Lantus prescription signed by your prescriber, proof of US residency, and a Medicaid denial letter if you may be Medicaid-eligible. Both you and your prescriber must sign the form. Submit by mail or fax; processing takes 7 to 14 business days. Approval lasts up to 12 months with an annual renewal. Income must be at or below 400 percent of the Federal Poverty Level.
Can I use the Sanofi Valyou Savings Program or copay card with Medicare?
No. Federal anti-kickback statute (42 U.S.C. § 1320a-7b) prohibits manufacturer savings cards and copay programs from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. The Sanofi Valyou Savings Program is available only to patients paying cash without using government insurance. Medicare beneficiaries pay the statutory $35-per-month insulin cap through their Part D plan. If that amount is still unaffordable, apply for Medicare Extra Help (Low Income Subsidy) at ssa.gov or through your State Health Insurance Assistance Program.
What if my insurance denies coverage for Lantus?
Request a written denial notice first. Then file a formal internal appeal within 60 days: ask your prescriber to submit a peer-to-peer clinical review and document medical necessity. If your plan requires step therapy using a biosimilar, your prescriber can file a step-therapy override citing a prior failed trial or clinical reason to remain on Lantus. If the internal appeal is denied, escalate to an external independent review through your state Department of Insurance. As a fallback, income-eligible patients can apply for the Sanofi Patient Connection PAP for free Lantus.
Does the IRA Medicare negotiated price apply to Lantus?
No. Lantus was not selected for Medicare price negotiation in IRA Round 1 or Round 2. CMS excluded insulin glargine from negotiation because multiple FDA-approved biosimilars already compete in the market, which disqualifies it from the single-source negotiation track. However, Lantus does benefit from the IRA's separate insulin-specific provision: the $35-per-month Part D cap for all Medicare beneficiaries, effective since January 1, 2023. Patients with Medicare Part D pay no more than $35 per month for Lantus regardless of their benefit phase.
What does Lantus cost without insurance at the pharmacy counter in 2026?
Without insurance or a discount program, Lantus retails at approximately $285 per 10 mL vial or $422 per box of five SoloSTAR pens in 2026. With the Sanofi Valyou Savings Program (register at lantus.com), uninsured and cash-paying patients pay $35 per 30-day supply. Using a GoodRx coupon at Costco or CVS, insulin glargine (generic equivalent) can be obtained for $57 to $80 per vial. The cheapest route for most cash-paying patients is the Valyou program for brand Lantus or a GoodRx coupon for a biosimilar such as Semglee.
Do I qualify for the Sanofi Patient Connection program?
To qualify for Sanofi Patient Connection, you must: be a US resident under the care of a US-licensed prescriber, have no prescription drug insurance coverage for Lantus or a biosimilar, and have a household income at or below 400 percent of the Federal Poverty Level. For 2026, the income limit is $63,840 for a single person, $132,000 for a household of four, and $222,880 for a household of eight. If you are potentially Medicaid-eligible, you must apply for Medicaid first and provide a denial letter. Medicare beneficiaries are not eligible for the PAP; they use the $35-per-month Part D insulin cap instead.
What is the difference between Lantus and Semglee, Basaglar, or Rezvoglar?
Lantus (Sanofi), Semglee (Viatris/Biocon), Basaglar (Eli Lilly), and Rezvoglar (Eli Lilly) all contain insulin glargine, a long-acting basal insulin that provides roughly 24-hour coverage. They are clinically comparable in blood glucose control. The key differences are cost and substitution rules: Semglee and Rezvoglar are FDA-designated interchangeable biosimilars, meaning a pharmacist can legally substitute them for a Lantus prescription without calling your doctor in most states. Basaglar is a follow-on biologic that requires a separate prescription. Insurance formularies often place biosimilars on preferred tiers, which means lower copays for those alternatives. Before switching, discuss the change with your prescriber to ensure dose and timing adjustments if needed.
